Send us a text

Dr. Oren Gilad, Ph.D., is President and Chief Executive Officer of Aprea Therapeutics ( https://aprea.com/ ), a clinical stage, platform biotechnology company focused on the development of novel, synthetic lethality-based therapies, with direct on-target mechanisms of action, and clear clinical pathways, that target various aspects of DNA Damage Response (DDR) Pathways.

Dr. Gilad previously served as President and CEO of Atrin Pharmaceuticals, Inc., leading its transaction with Aprea Therapeutics. 

Dr. Gilad brings extensive experience across multiple phases of drug development. During his time at Atrin, he led development from idea through early stage into the clinical stage while securing financing to support pre-clinical and clinical development, regulatory, and intellectual property activities. 

Before founding Atrin in 2011, Dr. Gilad authored several high-impact scientific publications over a 13-year academic career, including one demonstrating the importance of the ATR kinase pathway in cancer development and treatment. 

Dr. Gilad earned his doctorate in comparative pathology from the University of California at Davis, did his post-doc work at University of Pennsylvania School of Medicine, and his B.S. from the Hebrew University, Jerusalem, Israel.

#Cancer #Oncology #TumorBiology #OrenGilad #ApreaTherapeutics #Biotechnology #DrugDevelopment #Macrocycles #SyntheticLethality #DNADamageResponse #Doylestown #Philadelphia #ATRKinase #WEE1 #BRCA #PARP #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #Research

Support the show